Do analysts rate DRCT or TRAW?

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 85.19%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Direct Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Does the media prefer DRCT or TRAW?

In the previous week, Traws Pharma had 2 more articles in the media than Direct Digital. MarketBeat recorded 3 mentions for Traws Pharma and 1 mentions for Direct Digital. Direct Digital's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Direct Digital 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NNVC or TRAW more profitable?

NanoViricides' return on equity of -87.90% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Traws Pharma N/A -913.18% -133.88%

Does the media refer more to NNVC or TRAW?

In the previous week, Traws Pharma had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Traws Pharma and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TRAW or UG?

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 85.19%. Given Traws Pharma's higher probable upside, equities analysts plainly believe Traws Pharma is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor TRAW or UG?

In the previous week, Traws Pharma and Traws Pharma both had 3 articles in the media. United-Guardian's average media sentiment score of 0.51 beat Traws Pharma's score of 0.00 indicating that United-Guardian is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United-Guardian 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BGM or TRAW?

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 85.19%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Which has better earnings and valuation, BGM or TRAW?

Traws Pharma has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.77 -$19.94M N/A N/A Traws Pharma $2.79M 2.93 $9.17M -$1.69 N/A

Is BGM or TRAW more profitable?

BGM Group's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Traws Pharma N/A -913.18% -133.88%

Traws Pharma (TRAW) Competitors

$0.54 +0.01 (+1.50%)

As of 04:00 PM Eastern

Compare

TRAW vs. DRCT, SLGL, NNVC, UG, and BGM

Should you buy Traws Pharma stock or one of its competitors? Traws Pharma's main competitors and comparable companies include Direct Digital (DRCT), Sol-Gel Technologies (SLGL), NanoViricides (NNVC), United-Guardian (UG), and BGM Group (BGM). Companies are selected based on similarities in market, industry, and size.

How does Traws Pharma compare to Direct Digital?

Direct Digital (NASDAQ:DRCT) and Traws Pharma (NASDAQ:TRAW) are related small-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

4.0% of Direct Digital shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 25.6% of Direct Digital shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Traws Pharma has lower revenue, but higher earnings than Direct Digital. Traws Pharma is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Direct Digital	$34.69M	0.05	-$18.95M	-$201.62	N/A
Traws Pharma	$2.79M	2.93	$9.17M	-$1.69	N/A

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 85.19%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Direct Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Traws Pharma has a net margin of 0.00% compared to Direct Digital's net margin of -65.75%. Direct Digital's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Direct Digital	-65.75%	N/A	-59.57%
Traws Pharma	N/A	-913.18%	-133.88%

In the previous week, Traws Pharma had 2 more articles in the media than Direct Digital. MarketBeat recorded 3 mentions for Traws Pharma and 1 mentions for Direct Digital. Direct Digital's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Direct Digital	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Direct Digital has a beta of 5.32, indicating that its stock price is 432% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Summary

Traws Pharma beats Direct Digital on 8 of the 14 factors compared between the two stocks.

How does Traws Pharma compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, Traws Pharma had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 3 mentions for Traws Pharma and 0 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
Sol-Gel Technologies	Neutral
Traws Pharma	Neutral

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.28	-$6.13M	-$0.34	N/A
Traws Pharma	$2.79M	2.93	$9.17M	-$1.69	N/A

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 133.07%. Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 85.19%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Traws Pharma	N/A	-913.18%	-133.88%

Summary

Sol-Gel Technologies beats Traws Pharma on 11 of the 16 factors compared between the two stocks.

How does Traws Pharma compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

NanoViricides' return on equity of -87.90% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Traws Pharma	N/A	-913.18%	-133.88%

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Traws Pharma had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Traws Pharma and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides currently has a consensus price target of $6.00, suggesting a potential upside of 328.57%. Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 85.19%. Given NanoViricides' stronger consensus rating and higher possible upside, equities research analysts plainly believe NanoViricides is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Traws Pharma has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Traws Pharma	$2.79M	2.93	$9.17M	-$1.69	N/A

NanoViricides has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Summary

NanoViricides beats Traws Pharma on 8 of the 13 factors compared between the two stocks.

How does Traws Pharma compare to United-Guardian?

Traws Pharma (NASDAQ:TRAW) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

United-Guardian has a net margin of 22.01% compared to Traws Pharma's net margin of 0.00%. United-Guardian's return on equity of 22.61% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
United-Guardian	22.01%	22.61%	19.48%

In the previous week, Traws Pharma and Traws Pharma both had 3 articles in the media. United-Guardian's average media sentiment score of 0.51 beat Traws Pharma's score of 0.00 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United-Guardian	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Traws Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 7.6% of Traws Pharma shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Traws Pharma has higher earnings, but lower revenue than United-Guardian. Traws Pharma is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.93	$9.17M	-$1.69	N/A
United-Guardian	$10.55M	3.17	$2.11M	$0.54	13.48

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 85.19%. Given Traws Pharma's higher probable upside, equities analysts plainly believe Traws Pharma is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

United-Guardian beats Traws Pharma on 11 of the 14 factors compared between the two stocks.

How does Traws Pharma compare to BGM Group?

BGM Group (NASDAQ:BGM) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

BGM Group has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

In the previous week, Traws Pharma had 3 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Traws Pharma and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
Traws Pharma	Neutral

BGM Group's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Traws Pharma	N/A	-913.18%	-133.88%

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 85.19%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

8.0% of Traws Pharma shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Traws Pharma has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.77	-$19.94M	N/A	N/A
Traws Pharma	$2.79M	2.93	$9.17M	-$1.69	N/A

Summary

Traws Pharma beats BGM Group on 6 of the 11 factors compared between the two stocks.

Get Traws Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAW vs. The Competition

Export

Metric	Traws Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.06M	$11.84B	$7.02B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.32	788.51	269.19	24.71
Price / Sales	2.93	740.84	588.76	86.26
Price / Cash	0.70	15.12	28.89	37.42
Price / Book	-7.71	10.33	11.27	6.42
Net Income	$9.17M	$2.77B	$3.45B	$347.03M
7 Day Performance	14.50%	2.04%	3.56%	2.49%
1 Month Performance	-28.95%	-1.57%	-0.58%	-1.04%
1 Year Performance	-64.00%	191.33%	77.52%	23.22%

Traws Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAW Traws Pharma	2.6053 of 5 stars	$0.54 +1.5%	$1.00 +85.2%	-64.5%	$8.06M	$2.79M	N/A	17	Upcoming Earnings Gap Up
DRCT Direct Digital	0.8117 of 5 stars	$2.77 +2.6%	N/A	-97.2%	$2.01M	$34.69M	N/A	60	Gap Up
SLGL Sol-Gel Technologies	4.3469 of 5 stars	$88.00 +4.1%	$197.50 +124.4%	+450.3%	$237.42M	$19.39M	N/A	50
NNVC NanoViricides	1.4222 of 5 stars	$1.43 -5.9%	$6.00 +319.6%	-10.1%	$32.87M	N/A	N/A	20	News Coverage
UG United-Guardian	1.9897 of 5 stars	$7.21 +1.5%	N/A	-7.7%	$32.62M	$10.94M	13.87	20	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAW) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, NNVC, UG, and BGM

How does Traws Pharma compare to Direct Digital?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Summary

How does Traws Pharma compare to NanoViricides?

Summary

How does Traws Pharma compare to United-Guardian?

Summary

How does Traws Pharma compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, NNVC, UG, and BGM

How does Traws Pharma compare to Direct Digital?

Do insiders & institutionals believe in DRCT or TRAW?

Which has higher valuation & earnings, DRCT or TRAW?

Do analysts rate DRCT or TRAW?

Is DRCT or TRAW more profitable?

Does the media prefer DRCT or TRAW?

Which has more risk & volatility, DRCT or TRAW?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Does the media refer more to SLGL or TRAW?

Which has more volatility and risk, SLGL or TRAW?

Which has higher earnings & valuation, SLGL or TRAW?

Do insiders and institutionals believe in SLGL or TRAW?

Do analysts prefer SLGL or TRAW?

Is SLGL or TRAW more profitable?

Summary

How does Traws Pharma compare to NanoViricides?

Is NNVC or TRAW more profitable?

Do insiders & institutionals hold more shares of NNVC or TRAW?

Does the media refer more to NNVC or TRAW?

Do analysts recommend NNVC or TRAW?

Which has higher valuation and earnings, NNVC or TRAW?

Which has more volatility and risk, NNVC or TRAW?

Summary

How does Traws Pharma compare to United-Guardian?

Is TRAW or UG more profitable?

Does the media favor TRAW or UG?

Which has more volatility & risk, TRAW or UG?

Do insiders and institutionals hold more shares of TRAW or UG?

Which has better valuation and earnings, TRAW or UG?

Do analysts recommend TRAW or UG?

Summary

How does Traws Pharma compare to BGM Group?

Which has more volatility and risk, BGM or TRAW?

Does the media prefer BGM or TRAW?

Is BGM or TRAW more profitable?

Do analysts recommend BGM or TRAW?

Do insiders & institutionals hold more shares of BGM or TRAW?

Which has better earnings and valuation, BGM or TRAW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools